Selected studies of antibody-drug conjugates in lymphoma
| ADC . | Target . | Study phase . | Patient population . | Outcome(s) . |
|---|---|---|---|---|
| Brentuximab vedotin | CD30 | II38 | R/R cHL after ASCT failure | BV monotherapy |
| ORR of 75%, CR rate of 34% | ||||
| Median PFS of 5.6 mo | ||||
| Median DoR of 20.5 mo | ||||
| TRAEs: peripheral sensory neuropathy (42%), nausea (35%), fatigue (34%), neutropenia (19%), diarrhea (18%) | ||||
| III39 | R/R cHL after ASCT | Median PFS: 42.9 (BV) vs 24.1 mo (placebo) | ||
| AEs: peripheral sensory neuropathy (56% vs 16%), neutropenia (35% vs 12%) | ||||
| III40 | Previously untreated stage III or IV cHL | 2-y modified PFS: 82.1% (A+AVD) vs 77.2% (ABVD) | ||
| AEs: neutropenia (58% vs 45%), peripheral neuropathy (67% vs 43%), grade 3 or higher pulmonary toxicity (< 1% vs 3%) | ||||
| Moxetumomab pasudotox | CD22 | III11 | R/R HCL after at least 2 therapies | Moxetumomab pasudotox monotherapy |
| Durable CR rate of 30%, CR rate of 41%, ORR of 75% | ||||
| AEs: peripheral edema (39%), nausea (35%), fatigue (34%), headache (33%) | ||||
| Treatment related SAEs: HUS (7.5%), capillary leak syndrome (5%) | ||||
| Polatuzumab vedotin | CD79b | II12 | R/R DLBCL | Nonhematologic AEs: diarrhea (41% with pola+BR vs 21% with BR), infections (39% vs 41%), fatigue (36% vs 28%), pyrexia (33% vs 23%), IRR (31% vs 21%), peripheral neuropathy (39% vs 3%) |
| Hematologic AEs: neutropenia (54% vs 39%), thrombocytopenia (49% vs 23%), anemia (44% vs 15%) | ||||
| Grade 5 AEs: 18% in each arm | ||||
| ORR: 70% vs 33% | ||||
| CR: 58% vs 20% | ||||
| Median DoR: 8.8 vs 3.7 mo |
| ADC . | Target . | Study phase . | Patient population . | Outcome(s) . |
|---|---|---|---|---|
| Brentuximab vedotin | CD30 | II38 | R/R cHL after ASCT failure | BV monotherapy |
| ORR of 75%, CR rate of 34% | ||||
| Median PFS of 5.6 mo | ||||
| Median DoR of 20.5 mo | ||||
| TRAEs: peripheral sensory neuropathy (42%), nausea (35%), fatigue (34%), neutropenia (19%), diarrhea (18%) | ||||
| III39 | R/R cHL after ASCT | Median PFS: 42.9 (BV) vs 24.1 mo (placebo) | ||
| AEs: peripheral sensory neuropathy (56% vs 16%), neutropenia (35% vs 12%) | ||||
| III40 | Previously untreated stage III or IV cHL | 2-y modified PFS: 82.1% (A+AVD) vs 77.2% (ABVD) | ||
| AEs: neutropenia (58% vs 45%), peripheral neuropathy (67% vs 43%), grade 3 or higher pulmonary toxicity (< 1% vs 3%) | ||||
| Moxetumomab pasudotox | CD22 | III11 | R/R HCL after at least 2 therapies | Moxetumomab pasudotox monotherapy |
| Durable CR rate of 30%, CR rate of 41%, ORR of 75% | ||||
| AEs: peripheral edema (39%), nausea (35%), fatigue (34%), headache (33%) | ||||
| Treatment related SAEs: HUS (7.5%), capillary leak syndrome (5%) | ||||
| Polatuzumab vedotin | CD79b | II12 | R/R DLBCL | Nonhematologic AEs: diarrhea (41% with pola+BR vs 21% with BR), infections (39% vs 41%), fatigue (36% vs 28%), pyrexia (33% vs 23%), IRR (31% vs 21%), peripheral neuropathy (39% vs 3%) |
| Hematologic AEs: neutropenia (54% vs 39%), thrombocytopenia (49% vs 23%), anemia (44% vs 15%) | ||||
| Grade 5 AEs: 18% in each arm | ||||
| ORR: 70% vs 33% | ||||
| CR: 58% vs 20% | ||||
| Median DoR: 8.8 vs 3.7 mo |
A+AVD, BV-doxorubicin-vinblastine-dacarbazine; ABVD, doxorubicin-bleomycin-vinblastine-dacarbazine; ADC, antibody-drug conjugate; AEs, adverse events; ASCT, autologous stem cell transplantation; BR, bendamustine-rituximab; BV, brentuximab vedotin; cHL, classical Hodgkin lymphoma; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DoR, duration of response; HCL, hairy cell lymphoma; HUS, hemolytic uremic syndrome; IRR, infusion-related reaction; ORR, overall response rate; PFS, progression-free survival; pola, polatuzumab vedotin; SAEs, serious adverse events; TRAEs, treatment-related adverse events.